COVID-19: Second Phase Of Oxford Vaccine Trials Completed In Mumbai, BMC Set To Start Third Phase
Pune-based Serum Institute of India has partnered with AstraZeneca for manufacturing the Oxford COVID-19 vaccine candidate.
Oct 25, 2020 / 04:43 PM IST
The second phase of Oxford-AstraZeneca's experimental COVID-19 vaccine trials has been completed and the Brihanmumbai Municipal Corporation (BMC) will soon start the third phase of its clinical trials in Mumbai, Hindustan Times has reported.
According to the report, the third phase trials will start after the first batch of volunteers complete 28 days since their vaccination. The report states that as many as 200 health volunteers participated in the second phase of the trials, which were being conducted at King Edward Memorial (KEM) and BYL Nair hospitals.
"With the approval, we will be able to start the third phase of the trial once the first set of volunteers complete 28 days of the first vaccination. As per ICMR (Indian Council of Medical Research) guidelines, the third trial can only be conducted on volunteers after a gap of 28 days," BMC Additional Commissioner Suresh Kakani said.
Pune-based Serum Institute of India has partnered with AstraZeneca for manufacturing the Oxford COVID-19 vaccine candidate. SII is also conducting Phase 2 and 3 human clinical trials of the candidate in India.
Dr Suresh Jadhav, the executive director of the Serum Institute of India (SII), had earlier said that India might get its first vaccine in March 2021, provided regulators speed up the process as multiple manufacturers are working on it.
AstraZeneca has also resumed the US trial of its experimental COVID-19 vaccine after approval by regulators.